Yoshi-864 | CAS#3458-22-8 | DNA Crosslinker

MedKoo Cat#: 206573 | Name: Yoshi-864

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Yoshi-864 is an alkylsulfonate DNA crosslinker with potential anticancer activity. Yoshi-864 alkylates and crosslinks DNA, thereby inhibiting DNA replication.

Chemical Structure

Yoshi-864

CAS#3458-22-8

Theoretical Analysis

MedKoo Cat#: 206573

Name: Yoshi-864

CAS#: 3458-22-8

Chemical Formula: C8H20ClNO6S2

Exact Mass: 325.0421

Molecular Weight: 325.82

Elemental Analysis: C, 29.49; H, 6.19; Cl, 10.88; N, 4.30; O, 29.46; S, 19.68

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Improsulfan hydrochloride, Improsulfan HCl, Yoshi-864; Yoshi 864; Yoshi864; NSC102627; NSC-102627; NSC 102627

IUPAC/Chemical Name

azanediylbis(propane-3,1-diyl) dimethanesulfonate hydrochloride

InChi Key

YWCASUPWYFFUHE-UHFFFAOYSA-N

InChi Code

InChI=1S/C8H19NO6S2.ClH/c1-16(10,11)14-7-3-5-9-6-4-8-15-17(2,12)13;/h9H,3-8H2,1-2H3;1H

SMILES Code

CS(=O)(OCCCNCCCOS(=O)(C)=O)=O.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 325.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Douglass HO Jr, MacIntyre JM, Kaufman J, Von Hoff D, Engstrom PF, Klaassen D. Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine. Cancer Treat Rep. 1985 May;69(5):543-5. PubMed PMID: 2988774. 2: Slavik M, Muss H, Blessing JA. Phase II clinical study of Yoshi 864 in squamous cell carcinoma of the uterine cervix. Cancer Treat Rep. 1983 Feb;67(2):195-6. PubMed PMID: 6297730. 3: Altman SJ, Stephens RL, Bonnet JD. Yoshi 864 plus medroxyprogesterone acetate in adenocarcinoma of the kidney: A Southwest Oncology Group Study. Cancer Treat Rep. 1982 Sep;66(9):1781-2. PubMed PMID: 6288240. 4: Slavik M, Muss H, Blessing JA, Delgado G. Phase II clinical study of Yoshi 864 in epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. Cancer Treat Rep. 1982 Sep;66(9):1775-7. PubMed PMID: 6288239. 5: Meyn RE, Meistrich ML, White RA. Cycle-dependent anticancer drug cytotoxicity in mammalian cells synchronized by centrifugal elutriation. J Natl Cancer Inst. 1980 May;64(5):1215-9. PubMed PMID: 6154171. 6: Altman SJ, Metter GE, Nealon TF, Weiss AJ, Ramirez G, Madden RE, Fletcher WS, Strawitz JG, Multhauf PM. Yoshi 864 (1-propanol, 3,3'-iminodi-, dimethanesulfonate [ester], hydrochloride): a phase II study in solid tumors. Cancer Treat Rep. 1978 Mar;62(3):389-95. PubMed PMID: 206359. 7: Glae GR, Atkins LM, Meischen SJ, Smith AB, Walker EM Jr. Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents. J Natl Cancer Inst. 1976 Dec;57(6):1363-6. PubMed PMID: 187805. 8: Drewinko B, Barlogie B. Survival and cycle-progression delay of cultured human lymphoma cells treated with 1-propanol, 3,3'-iminodi-, dimethanesulfonate (ester), hydrochloride (Yoshi 864). Cancer Treat Rep. 1976 Nov;60(11):1637-45. PubMed PMID: 191191. 9: Gale GR, Smith AB, Atkins LM. Comparative effects of Yoshi-864 and busulfan on certain transplantable murine tumors. Proc Soc Exp Biol Med. 1975 May;149(1):98-101. PubMed PMID: 1170570. 10: Dowell KE, Armstrong DM, Aust JB, Cruz AB Jr. Systemic chemotherapy of advanced head and neck malignancies. Cancer. 1975 Apr;35(4):1116-20. PubMed PMID: 1116105. 11: Altman SJ, Fletcher WS, Andrews NC, Wilson WL, Pischer T. Yoshi 864 (NSC 102627) 1-propanol, 3, 3'-iminodi-dimethanesulfonate (ester) hydrochloride: a phase 1 study. Cancer. 1975 Apr;35(4):1145-7. PubMed PMID: 163676. 12: Hirano M, Miura M, Kakizawa H, Morita A, Uetani T, Ohno R, Kawashima K, Nishiwaki H, Yamada K. Treatment of chronic myelogenous leukemia with 3,3'-iminodi-1-propanol, dimethanesulfonate (ester), p-toluenesulfonate (NSC-140117) given orally. Cancer Chemother Rep. 1972 Jun;56(3):335-8. PubMed PMID: 19051492.